Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma

Journal of Clinical Oncology

Volumn 36, Issue 11, 2018, Pages 1128-1139

  Bollard, Catherine M ^a,b,c   Tripic, Tamara ^b   Cruz, Conrad Russell ^f   Dotti, Gianpietro ^b,c   Gottschalk, Stephen ^b,c   Torrano, Vicky ^b   Dakhova, Olga ^b   Carrum, George ^b,c   Ramos, Carlos A ^b,c   Liu, Hao ^c   Wu, Meng Fen ^c   Marcogliese, Andrea N ^c   Barese, Cecilia ^d   Zu, Youli ^d   Lee, Daniel Y ^d   O’Connor, Owen ^e   Gee, Adrian P ^b   Brenner, Malcolm K ^b,c   Heslop, Helen E ^b,c   Rooney, Cliona M ^b,c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA2 RECEPTOR TYPE 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL ENGINEERING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG DOSE ESCALATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ESCAPE;

EID: 85044231117     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.3179     Document Type: Article

References (35)

1. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311-319, 2015
2. Armand P: Immune checkpoint blockade in hematologic malignancies. Blood 125:3393-3400, 2015
3. Batlevi CL, Matsuki E, Brentjens RJ, et al: Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13:25-40, 2016
4. Bollard CM, Gottschalk S, Torrano V, et al: Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798-808, 2014
5. Ramos CA, Heslop HE, Brenner MK: CART cell therapy for lymphoma. Annu Rev Med 67: 165-183, 2016
6. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549, 2015
7. Riddell SR, Sommermeyer D, Berger C, et al: Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20:141-144, 2014
8. Chen R, Zinzani PL, Fanale MA, et al: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125-2132, 2017
9. Falchi L, Sawas A, Deng C, et al: High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol 9:132, 2016
10. Younes A, Santoro A, Shipp M, et al: Nivolu-mab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283-1294, 2016
11. Massagué J: TGF-beta signal transduction. Annu Rev Biochem 67:753-791, 1998
12. Bollard CM, Rössig C, Calonge MJ, et al: Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179-3187, 2002
13. Taylor GS, Long HM, Brooks JM, et al: The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787-821, 2015
14. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3068, 2014
15. Pule M. A., Savoldo B, Myers GD, et al: Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270, 2008
16. Chang ST, Ghosh D, Kirschner DE, et al: Peptide length-based prediction of peptide-MHC class II binding. Bioinformatics 22:2761-2767, 2006
17. + T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 99:93-99, 2002
18. Kern F, Faulhaber N, Frömmel C, et al: Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadeca-peptides. Eur J Immunol 30:1676-1682, 2000
19. + Hodgkin’s disease. J Exp Med 200:1623-1633, 2004
20. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 15:2652-2664, 2009
21. Foster AE, Dotti G, Lu A, et al: Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 31:500-505, 2008
22. Thomas D. A., Massagué J: TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380, 2005
23. Massagué J: TGFb signalling in context. Nat Rev Mol Cell Biol 13:616-630, 2012
24. Yin JJ, Selander K, Chirgwin JM, et al: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206, 1999
25. Gill S, June CH: Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263:68-89, 2015
26. Castellino SM, Geiger AM, Mertens AC, et al: Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 117:1806-1816, 2011
27. Younes A: Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol Oncol Clin North Am 28:27-32, 2014
28. Ramos CA, Ballard B, Zhang H, et al: Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 127:3462-3471, 2017
29. Gardner R, Wu D, Cherian S, et al: Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406-2410, 2016
30. Küppers R, Engert A, Hansmann ML: Hodgkin lymphoma. J Clin Invest 122:3439-3447, 2012
31. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2010
32. Papadopoulou A, Gerdemann U, Katari UL, et al: Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 6:242ra83, 2014
33. Rosenberg SA, Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62-68, 2015
34. + composition in adult B cell ALL patients. J Clin Invest 126:2123-2138, 2016
35. + CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8: 355ra116, 2016